Literature DB >> 28103033

Design, Synthesis, and Biological Evaluation of Small, High-Affinity Siglec-7 Ligands: Toward Novel Inhibitors of Cancer Immune Evasion.

Horst Prescher1, Martin Frank2, Stephan Gütgemann, Elena Kuhfeldt1, Astrid Schweizer3, Lars Nitschke3, Carsten Watzl, Reinhard Brossmer1.   

Abstract

Natural killer cells are able to directly lyse tumor cells, thereby participating in the immune surveillance against cancer. Unfortunately, many cancer cells use immune evasion strategies to avoid their eradication by the immune system. A prominent escape strategy of malignant cells is to camouflage themselves with Siglec-7 ligands, thereby recruiting the inhibitory receptor Siglec-7 expressed on the NK cell surface which subsequently inhibits NK-cell-mediated lysis. Here we describe the synthesis and evaluation of the first, high-affinity low molecular weight Siglec-7 ligands to interfere with cancer cell immune evasion. The compounds are Sialic acid derivatives and bind with low micromolar Kd values to Siglec-7. They display up to a 5000-fold enhanced affinity over the unmodified sialic acid scaffold αMe Neu5Ac, the smallest known natural Siglec-7 ligand. Our results provide a novel immuno-oncology strategy employing natural immunity in the fight against cancers, in particular blocking Siglec-7 with low molecular weight compounds.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28103033     DOI: 10.1021/acs.jmedchem.6b01111

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Siglec-7 on peripheral blood eosinophils: Surface expression and function.

Authors:  Fanny Legrand; Nadine Landolina; Ilan Zaffran; Robert O Emeh; Elizabeth Chen; Amy D Klion; Francesca Levi-Schaffer
Journal:  Allergy       Date:  2019-02-26       Impact factor: 13.146

Review 2.  Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.

Authors:  Alexander David Barrow; Marco Colonna
Journal:  Semin Immunol       Date:  2017-09-19       Impact factor: 11.130

3.  First Evidence for a Role of Siglec-8 in Breast Cancer.

Authors:  Anna Trebo; Nina Ditsch; Tom Degenhardt; Christina Kuhn; Martina Rahmeh; Elisa Schmoeckel; Doris Mayr; Bastian Czogalla; Thomas Kolben; Sarah Meister; Sven Mahner; Udo Jeschke; Anna Hester
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

Review 4.  Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.

Authors:  John Daly; Mattias Carlsten; Michael O'Dwyer
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

Review 5.  The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression.

Authors:  Yayun Zheng; Xue Ma; Dongmei Su; Yue Zhang; Lin Yu; Fangfei Jiang; Xue Zhou; Ying Feng; Fang Ma
Journal:  J Immunol Res       Date:  2020-04-06       Impact factor: 4.818

Review 6.  Sialic Acids and Their Influence on Human NK Cell Function.

Authors:  Philip Rosenstock; Thomas Kaufmann
Journal:  Cells       Date:  2021-01-29       Impact factor: 6.600

Review 7.  Siglec Ligands.

Authors:  Anabel Gonzalez-Gil; Ronald L Schnaar
Journal:  Cells       Date:  2021-05-20       Impact factor: 6.600

Review 8.  Tumor Microenvironment-Associated Extracellular Matrix Components Regulate NK Cell Function.

Authors:  Gustavo Rodrigues Rossi; Edvaldo S Trindade; Fernando Souza-Fonseca-Guimaraes
Journal:  Front Immunol       Date:  2020-01-29       Impact factor: 7.561

Review 9.  Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer.

Authors:  Simona Sivori; Mariella Della Chiesa; Simona Carlomagno; Linda Quatrini; Enrico Munari; Paola Vacca; Nicola Tumino; Francesca Romana Mariotti; Maria Cristina Mingari; Daniela Pende; Lorenzo Moretta
Journal:  Front Immunol       Date:  2020-09-03       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.